MODIFIED THERAPEUTIC AGENTS AND COMPOSITIONS THEREOF

1 - 41 . (canceled)

42 . A modified therapeutic agent (mTA) of Formula (I)

wherein

TA comprises an amino acid sequence that is at least 95% homologous to an amino acid sequence selected from SEQ ID NOS: 7-30;

a is 1 and b is 1;

Q is

A 1 is

R 3 and R 4 are H; and k are 2;

P 1 is PEG-A 2 ;

PEG is

wherein

m and n are each 1, 2, 3, or 4;

A 2 is

X is O; R 1 , R 2 , R 3 , and R 4 are H; R 7 is H; and r is 1;

or A 2 is

X is O; R 1 , R 2 , R 3 , and R 4 are H; each R 7 are H; r is 1; and s is 2; and

L is a lipid derivative selected from a group consisting of sterols, bile acids, vitamin E, fatty di-acids, fatty acids, fatty amides, fatty amines, and fatty alcohols; wherein the TA is covalently attached to

via two amino acid residues independently selected from lysine, ornithine, diaminobutyric acid, diaminopropionic acid, and homolysine on the amino acid sequence through the formation of an amide.

43 . The mTA of claim 42 , wherein the TA comprises an amino acid sequence that is at least 97% homologous to an amino acid sequence selected from SEQ ID NOS: 7-30.

44 . The mTA of claim 42 , wherein the TA comprises any one of SEQ ID NOS: 7-30.45.

45 . The mTA of claim 42 , wherein each of the two amino acid residues is lysine.

46 . The mTA of claim 42 , further comprising a second staple and a second half-life extending molecule, wherein the second half-life molecule is covalently attached to the second staple.

47 . The mTA of claim 42 , wherein the half-life of the mTA is longer than the half-life of the unmodified TA alone.

48 . The mTA of claim 42 , wherein the half-life of the mTA is at least 5-fold longer than the half-life of the unmodified TA alone.

49 . A pharmaceutical composition comprising the mTA of claim 42 and a pharmaceutically acceptable excipient.

50 . A method for treating a disease or condition in a subject in need thereof, the method comprising administering to the subject a composition comprising a therapeutically effective amount of the mTA of claim 42 .

51 . The method of claim 50 , wherein the disease or condition is diabetes or obesity, or a medical condition associated with diabetes, obesity, non-alcoholic fatty liver disease (NAFLD), nonalcoholic steatohepatitis (NASH), cardiovascular disease, short bowel syndrome (SBS), inflammatory bowel disease (IBD), inflammatory bowel syndrome (IBS), psoriasis, Crohn's disease, ulcerative colitis, Alzheimer's disease, Parkinson's disease, Huntington's disease.

52 . The method of claim 51 , further comprising administering to the subject one or more additional therapeutic agents.

53 . The method of claim 52 , wherein the one or more additional therapeutic agents is selected from a group consisting of other diabetes drugs, DPP4 inhibitors, SGLT2 inhibitors, hypoglycemic drugs and biguanidine drugs, insulin secretogogues and sulfonyl urea drugs, TZD drugs, insulin and insulin analogs, FGF21 and analogs, leptin or leptin analogs, amylin and amylin analogs, an anti-inflammatory drug, cyclosporine A or FK506, 5-ASA, and a statin, or any combination thereof.

54 . A method for treating a disease or condition in a subject in need thereof, the method comprising administering to the subject a composition comprising a therapeutically effective amount of the mTA of claim 44 .

55 . The method of claim 54 , wherein the disease or condition is diabetes or obesity, or a medical condition associated with diabetes, obesity, non-alcoholic fatty liver disease (NAFLD), nonalcoholic steatohepatitis (NASH), cardiovascular disease, short bowel syndrome (SBS), inflammatory bowel disease (IBD), inflammatory bowel syndrome (IBS), psoriasis, Crohn's disease, ulcerative colitis, Alzheimer's disease, Parkinson's disease, Huntington's disease.

56 . The method of claim 55 , further comprising administering to the subject one or more additional therapeutic agents.

57 . The method of claim 56 , wherein the one or more additional therapeutic agents is selected from a group consisting of other diabetes drugs, DPP4 inhibitors, SGLT2 inhibitors, hypoglycemic drugs and biguanidine drugs, insulin secretogogues and sulfonyl urea drugs, TZD drugs, insulin and insulin analogs, FGF21 and analogs, leptin or leptin analogs, amylin and amylin analogs, an anti-inflammatory drug, cyclosporine A or FK506, 5-ASA, and a statin, or any combination thereof.